The $200B Patent Cliff Meets 3.2 Billion Patients: How Generic Drug Manufacturers Win in BRICS
The global generic drug market is not growing uniformly. It is concentrating. Between 2025 and 2030, branded drugs accounting for […]
The $400 Billion Patent Cliff Big Pharma Can’t Avoid
Why a 20-Year Patent Rarely Means 20 Years of Revenue The statutory term creates a false ceiling. The effective commercial
The $400 Billion Patent Cliff Big Pharma Can’t Avoid Read Post »
Russia Pharma Market Entry: IP Strategy, Patent Risks, and the Localization Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors assessing Russia exposure in 2025-2030. The Rouble Economy: Why
Russia Pharma Market Entry: IP Strategy, Patent Risks, and the Localization Playbook Read Post »
How PTAB Actually Invalidates Drug Patents — And How to Stop It
The “patent death squad” label has haunted PTAB since 2012. The actual data tells a different story — one where
How PTAB Actually Invalidates Drug Patents — And How to Stop It Read Post »
The $50B Patent Problem: How to Protect Drugs That Are Part Biologic, Part Small Molecule
Combination drugs — pairing a biologic with a small molecule — are among the most commercially valuable assets in pharma.
The $700B Generic Drug Opportunity Big Pharma Is Still Getting Wrong
The global generic drug market will cross $700 billion by 2032. Most of that growth will not come from the
The $700B Generic Drug Opportunity Big Pharma Is Still Getting Wrong Read Post »
How ANDA Timing Wins Generic Drug Markets: The Complete Patent Strategy Playbook
Generic drugs fill 90% of U.S. prescriptions and capture 18% of revenue. That gap is the whole game. The companies
How ANDA Timing Wins Generic Drug Markets: The Complete Patent Strategy Playbook Read Post »
The $200B Complex Generic Opportunity Big Pharma Is Ignoring
A technical and commercial intelligence guide to complex generic development, patent strategy, regulatory sequencing, and emerging market positioning for pharma
The $200B Complex Generic Opportunity Big Pharma Is Ignoring Read Post »
The $926B Generic Drug Race: How to Win Before the Patent Clock Runs Out
The generic drug industry operates on a paradox that never fully resolves. Generic and biosimilar medicines fill 90% of all
The $926B Generic Drug Race: How to Win Before the Patent Clock Runs Out Read Post »
